Contribute Try STAT+ Today

Where does Biogen (BIIB) go from here?

The announcement from the Cambridge, Mass.-based biotech company that it is stopping two clinical trials of its Alzheimer’s drug aducanumab is certainly bad for patients, their families, and for anyone worried about developing this terrible, brain-destroying disease. It’s frustrating for researchers who believed medicines like aducanumab had some hope of slowing an affliction that has stymied all attempts at treating it for a decade and a half.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.